Hikma delivers excellent first half results with 16% revenue growth

August 20, 2014 1:13 pm

Hikma Pharmaceuticals PLC (“Hikma”), the fast growing multinational pharmaceutical group with operations across the Middle East and North Africa (MENA), Europe and the US, reports its interim results for the six months ended 30 June 2014.

Group revenue increased by 16% to $738 million, driven by the strong performance of the Injectables business. Hikma continued to build its global product portfolio by introducing new products to its markets. A total of 49 products were launched and 140 product approvals were received in the first half of 2014.

Mr. Said Darwazah, Chief Executive Officer of Hikma, said: “I am very pleased with our first half results, which reflect strong underlying performance in our businesses and our success in capturing a number of specific market opportunities. In the MENA region, our focus on new, higher value products is delivering strong results in key markets. Our Injectables business delivered an excellent performance, as we captured a number of attractive market opportunities. I am delighted we have acquired the Bedford assets, which will add products, R&D capabilities and capacity to support future growth for the global Injectables business. Our Generics business is performing extremely well and we are working hard to strengthen the product portfolio and pipeline. Overall, the Group is benefiting from our diversified business model and I am pleased to be reiterating our Group continued revenue growth for the full year.”

Hikma contributes to developing communities in areas where it works and improving the quality of life. It supports sustainable initiatives and encourages its employees to volunteer. Through Hikma’s annual Global Volunteering Day, employees volunteered to fight hunger and addressed the problem of malnutrition in Jordan and various environmental and health-related initiatives were held across the Group.

As a committed corporate citizen, Hikma Pharmaceuticals donated medicines to Palestinians in Gaza due to the severe shortage in medicines and medical supplies in their hospitals and to alleviate their suffering.

Hikma also launched an innovative mobile application, “Hikma Health App” that helps patients store health records, take medications on time and take control of their health. It provides users with possible causes for their symptoms that is intended for informational purposes only and does not substitute professional medical advice.